



PUBLICATIONS

1. Rios JL, Sapède D, Djouad F, et al. [Animal Models of Osteoarthritis Part 1-Preclinical Small Animal Models: Challenges and Opportunities for Drug Development](#). Current Protocols. 2022 Nov;2(11):e596. DOI: 10.1002/cpz1.596. PMID: 36342311.
2. Loef M, van de Stadt L, Böhringer S, Bay-Jensen AC, Mobasheri A, **Larkin J**, Lafeber FPJG, Blanco FJ, Haugen IK, Berenbaum F, Giera M, Ioan-Facsinay A, Kloppenburg M. [The association of the lipid profile with knee and hand osteoarthritis severity: the IMI-APPROACH cohort](#). Osteoarthritis Cartilage. 2022 Aug;30(8):1062-1069. doi: 10.1016/j.joca.2022.05.008. Epub 2022 May 27. PubMed PMID: 35644463.
3. van Helvoort EM, Jansen MP, Marijnissen ACA, Kloppenburg M, Blanco FJ, Haugen IK, Berenbaum F, Bay-Jensen AC, Ladel C, Lalande A, **Larkin J**, Loughlin J, Mobasheri A, Weinans HH, Widera P, Bacardit J, Welsing PMJ, Lafeber FPJG. [Predicted and actual 2-year structural and pain progression in the IMI-APPROACH knee osteoarthritis cohort](#). Rheumatology (Oxford). 2022 May 16;. doi: 10.1093/rheumatology/keac292. [Epub ahead of print] PubMed PMID: 35575381.
4. Angelini F, Widera P, Mobasheri A, Blair J, Struglics A, Uebelhoer M, Henrotin Y, Marijnissen AC, Kloppenburg M, Blanco FJ, Haugen IK, Berenbaum F, Ladel C, **Larkin J**, Bay-Jensen AC, Bacardit J. [Osteoarthritis endotype discovery via clustering of biochemical marker data](#). Ann Rheum Dis. 2022 May;81(5):666-675. doi: 10.1136/annrheumdis-2021-221763. Epub 2022 Mar 4. PubMed PMID: 35246457.
5. van Helvoort EM, Welsing PMJ, Jansen MP, Gielis WP, Loef M, Kloppenburg M, Blanco F, Haugen IK, Berenbaum F, Bay-Jensen AC, Ladel C, Lalande A, **Larkin J**, Loughlin J, Mobasheri A, Weinans H, Lafeber F, Eijkelkamp N, Mastbergen S. [Neuropathic pain in the IMI-APPROACH knee osteoarthritis cohort: prevalence and phenotyping](#). RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-002025. PubMed PMID: 34911812; PubMed Central PMCID: PMC8679113.
6. He Y, Jensen KE, Siebuhr A, Karsdal MA, **Larkin J**, Bay-Jensen AC. Development of a highly sensitive chemiluminescence immunoassay for quantification of aggrecanase-generated ARGS aggrecan fragments in serum. Osteoarthritis and Cartilage Open. 2021 June; 3(2). Taylor J, Dekker S, Jurg D, Skandsen J, Grossman M, Marijnissen AK, Ladel C, Mobasheri A, Larkin J, Weinans H, Kanter-Schlifke I. [Making the patient voice heard in a research consortium: experiences from an EU project \(IMI-APPROACH\)](#). Res Involv Engagem. 2021 May 10;7(1):24. doi: 10.1186/s40900-021-00267-0. PubMed PMID: 33971982; PubMed Central PMCID: PMC8107424.
7. van Helvoort EM, van Spil WE, Jansen MP, Welsing PMJ, Kloppenburg M, Loef M, Blanco FJ, Haugen IK, Berenbaum F, Bacardit J, Ladel CH, Loughlin J, Bay-Jensen AC, Mobasheri A, **Larkin J**, Boere J, Weinans HH, Lalande A, Marijnissen ACA, Lafeber FPJG. [Cohort profile: The Applied Public-Private Research enabling OsteoArthritis Clinical Headway \(IMI-APPROACH\) study: a 2-year, European, cohort study to describe, validate and predict phenotypes of osteoarthritis using clinical, imaging and biochemical markers](#). BMJ Open. 2020 Jul 28;10(7):e035101. doi: 10.1136/bmjopen-2019-035101. PubMed PMID: 32723735; PubMed Central PMCID: PMC7389775.
8. Widera P, Welsing PMJ, Ladel C, Loughlin J, Lafeber PPFJ, Petit Dop F, **Larkin J**, Weinans H, Mobasheri A, Bacardit J. [Multi-classifier prediction of knee osteoarthritis progression from incomplete imbalanced longitudinal data](#). Sci Rep. 2020 May 21;10(1):8427. doi: 10.1038/s41598-020-64643-8. PubMed PMID: 32439879; PubMed Central PMCID: PMC7242357.
9. Tona RM, McDonald TAO, Akhavein N, **Larkin JD**, Lai D. [Microfluidic droplet liquid reactors for active pharmaceutical ingredient crystallization by diffusion controlled solvent extraction](#). Lab Chip. 2019 Jun 11;19(12):2127-2137. doi: 10.1039/c9lc00204a. PubMed PMID: 31114833.
10. Hodgins D, Bay-Jensen A, Boere J, Hussaarts L, Ladel C, Lalande A, **Larkin J**, Loughlin J, Mobasheri A, Palozzi L, Weinans H, Lafeber F, Berenbaum F, Blanco F, Haugen I, Kloppenburg M, Marijnissen A, van Helvoort E, van Spil W, Hodgins D. [Gait kinematics for patients with early-stage knee osteoarthritis in the approach project](#). Osteoarthritis Cartilage. April 2019; 27(S1):S114-115.
11. He Y, Ronberg H, Karsdal M, Siebuhr A, **Larkin J**, Bay-Jensen AC. Reestablishment of the ARGS pharmacodynamic, serum biomarker. Development of a high sensitive chemiluminescence immunoassay for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage. April 2019; 27(S1):S109-110.



PUBLICATIONS - CONTINUED

12. Eckstein F, Maschek S, Bay-Jensen A, Boere J, Hussaarts L, Ladel C, Lalande A, **Larkin J**, Loughlin J, Mobasheri A, Palozzi L, Weinans H, Lafeber FP, Berenbaum F, Soler R, Blanco FJ, Isaksen T, Haugen IH, Loef M, Kloppenburg M, Marijnissen AC, van Helvoort E, van Spil WE, Roemer F, Wirth W. Intersite comparison and test-retest reliability of cartilage thickness and compositional analysis in the approach study - a 2-year multicenter European exploratory study for phenotype characterization of knee osteoarthritis. *Osteoarthritis and Cartilage*. 2019 April; 27(S1):S326-S327.
13. Mobasheri A, van Spil WE, Budd E, Uzieliene I, Bernotiene E, Bay-Jensen AC, **Larkin J**, Levesque MC, Gualillo O, Henrotin Y. [Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes](#). *Curr Opin Rheumatol*. 2019 Jan;31(1):80-89. doi: 10.1097/BOR.0000000000000567. Review. PubMed PMID: 30461544.
14. Mobasheri A, Bay-Jensen AC, Gualillo O, **Larkin J**, Levesque MC, Henrotin Y. [Soluble biochemical markers of osteoarthritis: Are we close to using them in clinical practice?](#). *Best Pract Res Clin Rheumatol*. 2017 Oct;31(5):705-720. doi: 10.1016/j.berh.2018.07.002. Epub 2018 Sep 11. Review. PubMed PMID: 30509415.
15. Mobasheri A, Bay-Jensen AC, van Spil WE, **Larkin J**, Levesque MC. [Osteoarthritis Year in Review 2016: biomarkers \(biochemical markers\)](#). *Osteoarthritis Cartilage*. 2017 Feb;25(2):199-208. doi: 10.1016/j.joca.2016.12.016. Epub 2017 Jan 16. Review. PubMed PMID: 28099838.
16. Miller RE, Tran PB, Ishihara S, **Larkin J**, Malfait AM. [Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis](#). *Osteoarthritis Cartilage*. 2016 Feb;24(2):299-306. doi: 10.1016/j.joca.2015.09.005. Epub 2015 Sep 26. PubMed PMID: 26410555; PubMed Central PMCID: PMC4743933.
17. **Larkin J**, Lohr TA, Elefante L, Shearin J, Matico R, Su JL, Xue Y, Liu F, Genell C, Miller RE, Tran PB, Malfait AM, Maier CC, Matheny CJ. [Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification](#). *Osteoarthritis Cartilage*. 2015 Aug;23(8):1254-66. doi: 10.1016/j.joca.2015.02.778. Epub 2015 Mar 20. PubMed PMID: 25800415; PubMed Central PMCID: PMC4516626.
18. Foulcer SJ, Nelson CM, Quintero MV, Kuberan B, **Larkin J**, Dours-Zimmermann MT, Zimmermann DR, Apte SS. [Determinants of versican-V1 proteoglycan processing by the metalloproteinase ADAMTS5](#). *J Biol Chem*. 2014 Oct 3;289(40):27859-73. doi: 10.1074/jbc.M114.573287. Epub 2014 Aug 13. PubMed PMID: 25122765; PubMed Central PMCID: PMC4183820.
19. Germaschewski FM, Matheny CJ, **Larkin J**, Liu F, Thomas LR, Saunders JS, Sully K, Whittall C, Boyle Y, Peters G, Graham NM. [Quantitation OF ARGS aggrecan fragments in synovial fluid, serum and urine from osteoarthritis patients](#). *Osteoarthritis Cartilage*. 2014 May;22(5):690-7. doi: 10.1016/j.joca.2014.02.930. Epub 2014 Feb 28. PubMed PMID: 24583346.
20. Germaschewski FM, Matheny CJ, **Larkin J**, Liu F, Thomas LR, Saunders JS, Sully K, Whittall C, Boyle Y, Peters G, Graham NM. [Quantitation OF ARGS aggrecan fragments in synovial fluid, serum and urine from osteoarthritis patients](#). *Osteoarthritis Cartilage*. 2014 May;22(5):690-7. doi: 10.1016/j.joca.2014.02.930. Epub 2014 Feb 28. PubMed PMID: 24583346.
21. Gremschewski F, **Larkin JD**, Liu F, Lohr T, inventors. GlaxoSmithKline, assignee. *Methods of Identifying a Patient Population*. United States patent application 20130336989. 2013 December.
22. Thorneloe KS, Cheung M, Bao W, Alsaïd H, Lenhard S, Jian MY, Costell M, Maniscalco-Hauk K, Krawiec JA, Olzinski A, Gordon E, Lozinskaya I, Elefante L, Qin P, Maticic DS, James C, Tunstead J, Donovan B, Kallal L, Waszkiewicz A, Vaidya K, Davenport EA, **Larkin J**, Burgert M, Casillas LN, Marquis RW, Ye G, Eidam HS, Goodman KB, Toomey JR, Roethke TJ, Jucker BM, Schnackenberg CG, Townsley MI, Lepore JJ, Willette RN. [An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure](#). *Sci Transl Med*. 2012 Nov 7;4(159):159ra148. doi: 10.1126/scitranslmed.3004276. PubMed PMID: 23136043.
23. Deng H, O'Keefe H, Davie CP, Lind KE, Acharya RA, Franklin GJ, **Larkin J**, Matico R, Neeb M, Thompson MM, Lohr T, Gross JW, Centrella PA, O'Donovan GK, Bedard KL, van Vloten K, Mataruse S, Skinner SR, Belyanskaya SL, Carpenter TY, Shearer TW, Clark MA, Cuzzo JW, Arico-Muendel CC, Morgan BA. [Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology \(ELT\)](#). *J Med Chem*. 2012 Aug



PUBLICATIONS - CONTINUED

24. **Larkin J.** Linking an ADAMTS5-specific therapeutic monoclonal antibody to a sensitive biochemical marker of target engagement and activity for potential application as a companion diagnostic. *Osteoarthritis and Cartilage*. 2012 April; 20(S1):S290.
25. **Larkin J**, inventor. GlaxoSmithKline, assignee. Anti-adamts4 antibodies and methods of treatment. United States patent application WO2013109829A1. 2012 January.
26. Burden MN, Hamblin PA, **Larkin JD**, White JR, inventors. GlaxoSmithKline, assignee. Polypeptides and Method of Treatment. United States patent application WO2011002968A3. 2011 January.
27. **Larkin J**, Bost A, Glass JI, Tan SL. [Cytokine-activated natural killer cells exert direct killing of hepatoma cells harboring hepatitis C virus replicons](#). *J Interferon Cytokine Res*. 2006 Dec;26(12):854-65. doi: 10.1089/jir.2006.26.854. PubMed PMID: 17238828.
28. **Larkin J**, Renukaradhya GJ, Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. [CD44 differentially activates mouse NK T cells and conventional T cells](#). *J Immunol*. 2006 Jul 1;177(1):268-79. doi: 10.4049/jimmunol.177.1.268. PubMed PMID: 16785522.
29. Norton PA, Reis HM, Prince S, **Larkin J**, Pan J, Liu J, Gong Q, Zhu M, Feitelson MA. [Activation of fibronectin gene expression by hepatitis B virus x antigen](#). *J Viral Hepat*. 2004 Jul;11(4):332-41. doi: 10.1111/j.1365-2893.2004.00555.x. PubMed PMID: 15230856.
30. Feitelson MA, **Larkin JD**, Schinazi RF. [Hepatitis B virus transgenic severe combined immunodeficient mouse model of acute and chronic liver disease](#). *Methods Mol Med*. 2004;96:269-87. doi: 10.1385/1-59259-670-3:269. PubMed PMID: 14762277.
31. **Larkin J**, Jin L, Farmen M, Venable D, Huang Y, Tan SL, Glass JI. [Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system](#). *J Interferon Cytokine Res*. 2003 May;23(5):247-57. doi: 10.1089/107999003321829962. PubMed PMID: 12804067.
32. **Larkin J**, Clayton MM, Liu J, Feitelson MA. [Chronic ethanol consumption stimulates hepatitis B virus gene expression and replication in transgenic mice](#). *Hepatology*. 2001 Oct;34(4 Pt 1):792-7. doi: 10.1053/jhep.2001.27565. PubMed PMID: 11584377.
33. Feitelson MA, **Larkin JD**. [New animal models of hepatitis B and C](#). *ILAR J*. 2001;42(2):127-38. doi: 10.1093/ilar.42.2.127. Review. PubMed PMID: 11406715.
34. **Larkin J**, Clayton M, Sun B, Perchonock CE, Morgan JL, Siracusa LD, Michaels FH, Feitelson MA. [Hepatitis B virus transgenic mouse model of chronic liver disease](#). *Nat Med*. 1999 Aug;5(8):907-12. doi: 10.1038/11347. PubMed PMID: 10426314.
35. Slater SJ, Kelly MB, **Larkin JD**, Ho C, Mazurek A, Taddeo FJ, Yeager MD, Stubbs CD. [Interaction of alcohols and anesthetics with protein kinase Calpha](#). *J Biol Chem*. 1997 Mar 7;272(10):6167-73. doi: 10.1074/jbc.272.10.6167. PubMed PMID: 9045629.
36. Slater SJ, Kelly M, Yeager MD, **Larkin J**, Ho C, Stubbs CD. Polyunsaturation in cell membranes and lipid bilayers and its effects on membrane proteins. *Lipids*. 1996 Jan; 31(1):S189-192.
37. Slater SJ, Ho C, Kelly MB, **Larkin JD**, Taddeo FJ, Yeager MD, Stubbs CD. Protein kinase C α contains two activator binding sites that bind phorbol esters and diacylglycerols with opposite affinities. *J Biol Chem*. 1996 Mar; 271(9):P4627-4631.
38. Slater SJ, Kelly MB, Taddeo FJ, **Larkin JD**, Yeager MD, McLane JA, Ho C, Stubbs CD. Direct Activation of Protein Kinase C by 1 α ,25-Dihydroxyvitamin D $_3$. *J Biol Chem*. 1995 Mar; 270(12):P6639-6643.